Lantheus Holdings(US:LNTH) Prnewswireยท2025-09-12 02:26Core Viewpoint - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Lantheus Holdings, Inc. due to allegations of providing misleading business information to investors [1]. Company Overview - Lantheus Holdings, Inc. is a globally recognized company focused on the development, production, and distribution of advanced diagnostic and therapeutic products, with core expertise in oncology and cardiovascular care [3]. Alleged Wrongdoing - On August 6, 2025, Lantheus reported weaker-than-expected second-quarter results, missing earnings and revenue targets. The company cut its full-year 2025 revenue and EPS forecasts, citing tougher competition in the PSMA PET imaging market and strategic pullbacks from certain accounts [4]. - Revenue for the quarter fell to $378 million, down 4.1%, with PYLARIFY sales dropping 8.3% to $250.6 million, both below projections [4]. Market Reaction - Following the news of the disappointing results, Lantheus stock price fell by $20.76 per share, or 28.58%, closing at $51.87 per share on August 6, 2025 [5].